NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) announced today that its global patent portfolio has reached 176 patents, significantly reinforcing the biopharmaceutical company's competitive position in the oncology and neurology therapeutic spaces.
The company's intellectual property portfolio currently includes 126 issued patents—29 in the United States and 97 internationally—along with 50 pending patent applications across global markets. This extensive coverage spans all major pharmaceutical territories, including the United States, European Union, China, Japan, Brazil, and Australia.
"Intellectual property is a cornerstone of our strategy, and the strength of our global patent portfolio reflects the depth of our innovation and the breadth of our ambition," said Amir Heshmatpour, Executive Chairman and President of NeOnc Technologies. "This portfolio enhances our ability to protect our breakthroughs in oncology and neurology, including our intranasal drug delivery platform, and safeguards our proprietary capability to bio-conjugate existing standard-of-care treatments like TMZ."
Strategic Patent Protection for Lead Programs
NeOnc's patent strategy provides comprehensive protection for its pipeline of novel therapeutics, with particular focus on its lead programs:
-
NEO100: This ultrapure perillyl alcohol formulation is protected by eight U.S. patents with expiration dates between 2031 and 2036. The compound may receive additional exclusivity through the FDA's patent term extension program and benefits from Orphan Drug Designation.
-
NEO212 and NEO214: These structurally unique perillyl alcohol conjugates qualify for Orange Book eligibility and new chemical entity data exclusivity provisions following regulatory approval.
-
NEO400: This topical anticancer agent recently secured broad patent coverage in Europe, with similar global filings in progress.
The company also holds strategic patents for its blood-brain barrier permeabilization technology, with protections extending to 2039—a critical advantage in developing central nervous system therapeutics.
Clinical Progress Backed by IP Strategy
NeOnc's NEO100 and NEO212 therapeutics are currently advancing through Phase II human clinical trials under FDA Fast-Track and Investigational New Drug (IND) status. These compounds have demonstrated promising effects in laboratory tests on various cancer types and in clinical trials treating malignant gliomas.
Dr. Thomas Chen, CEO of NeOnc Technologies, emphasized the importance of the company's patent estate: "Our mission is to bring paradigm-shifting therapies to patients with some of the most challenging conditions, and our growing patent estate gives us the platform to do just that. We will continue to invest aggressively in IP as we advance toward clinical and regulatory milestones across our pipeline."
Addressing Critical Treatment Challenges
NeOnc Technologies is focused on overcoming one of the most persistent challenges in treating central nervous system conditions—the blood-brain barrier. The company's NEO drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038.
The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California, consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.
Market Implications
For investors and industry observers, NeOnc's robust patent portfolio represents a significant barrier to entry for potential competitors and provides a foundation for long-term value creation. The company's strategic approach to intellectual property protection across global markets positions it favorably as it advances its therapeutic candidates toward regulatory approval.
As the company progresses through clinical development stages, this intellectual property foundation may prove crucial in attracting potential partnerships and securing market position upon eventual commercialization of its novel therapeutics.
